Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | HTR1F | P30939 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499070 | 1.00 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| Oxalic Acid SCHEMBL5762121 | 0.96 | HTR6 (0.92) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5499078 | 0.93 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5498952 | 0.90 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5498885 | 0.89 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5502542 | 0.89 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5501752 | 0.89 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5505546 | 0.87 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL7442969 | 0.86 | HTR6 (0.79) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL5502012 | 0.86 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382499-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2024-11-21 | — | — | US | disclosed |
| EP-4277706-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022154664-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-07-21 | — | — | WO | disclosed |